About New Iridium
New Iridium is a company based in Boulder (United States) founded in 2016 by Garrett Miyake, Chern-Hooi Lim, and Brent Cutcliffe. New Iridium has raised $2.65 million across 6 funding rounds from investors including HHS, CIRI Ventures and National Science Foundation. New Iridium operates in a competitive market with competitors including Sai Life Sciences, Acies Bio, Liverpool ChiroChem, SpiroChem and IRBM, among others.
- Headquarter Boulder, United States
- Founders Garrett Miyake, Chern-Hooi Lim, Brent Cutcliffe
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.65 M (USD)
in 6 rounds
-
Latest Funding Round
$2.65 M (USD), Seed
Jun 11, 2025
-
Investors
HHS
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of New Iridium
New Iridium has successfully raised a total of $2.65M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $2.65 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in New Iridium
New Iridium has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, CIRI Ventures and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment firm fueling climate innovation at pre-seed and seed stages
|
Locked | Locked | Locked |
Investor details for New Iridium
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by New Iridium
Investment portfolio details for New Iridium
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - New Iridium
Detailed financials for New Iridium
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
New Iridium Comparisons
Peer comparison for New Iridium
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of New Iridium
New Iridium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sai Life Sciences, Acies Bio, Liverpool ChiroChem, SpiroChem and IRBM, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Provider of drug discovery and development services to pharmaceutical, biotech, and food industries
|
|
| Locked | Locked | Locked |
Small organic molecules are supplied for biotech and pharmaceutical R&D.
|
|
| Locked | Locked | Locked |
Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry
|
|
| Locked | Locked | Locked |
Integrated drug discovery and preclinical development services are provided.
|
|
| Locked | Locked | Locked |
Coherent Synthesis is developed for medicinal and combinatorial chemistry applications.
|
Detailed competitors of New Iridium
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on New Iridium
Complete news archive for New Iridium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about New Iridium
New Iridium was founded in 2016 and raised its 1st funding round 3 years after it was founded.
New Iridium is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Chern-Hooi Lim is the current CEO of New Iridium. They have also founded this company.
New Iridium is a funded company, having raised a total of $2.65M across 6 funding rounds to date.
New Iridium was established in 2016 and is based in Boulder, United States. Operations center on chemical manufacturing, with a focus on producing phenoxazine and dihydrophenazine compounds. The company is led by co-founders Chern-Hooi Lim as CEO, Garrett Miyake as CTO, and Brent Cutcliffe as COO. Activities are conducted within the specialty chemicals sector, serving industrial needs through targeted synthesis processes.
New Iridium's top competitors include Sai Life Sciences, Acies Bio and Liverpool ChiroChem.
New Iridium has 7 investors. Key investors include HHS, CIRI Ventures, National Science Foundation, America’s Seed Fund, and Radicle.